FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2612851504> ?p ?o ?g. }

• W2612851504 endingPage "209" @default.
• W2612851504 startingPage "204" @default.
• W2612851504 abstract "Objective: To investigate the clinical implications of p16 gene deletion in adult Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph(+) ALL) . Methods: Retrospective analysis of clinical, immunophenotypic, cytogenetics, molecular characteristics and prognosis of 80 newly diagnosed Ph(+) ALL patients with p16 deletion. Results: Of 80 adult Ph(+) ALL, the prevalence of p16 gene deletion was 31.3%. p16 gene deletion carriers frequently accompanied with high WBC counts (WBC≥30×10(9)/L) and CD20 expression. The incidence of complex chromosome abnormality in p16 gene deletion group was higher than that in non-deletion group, with alternations in chromosome 7, 8, 19 and der (22) more frequently observed. There was no difference occurred between patients with or without p16 gene deletion in complete remission (CR) rate following induction chemotherapy combined with tyrosine kinase inhibitors (TKIs) . However, after three cycles of chemotherapy, the MMR and CMR rate in the p16 gene deletion group was lower than patients with wild-type p16 gene (P=0.034, P=0.036) . The p16 gene deletion patients showed no significant differences in MMR, CMR and relapse rate between Imatinib or Dasatinib plus chemotherapy (P>0.05) . Deletion of p16 gene was significantly associated with poor outcomes including worse overall survival (OS) (37.1% vs 54.1%, P=0.037) , lower disease free-survival (DFS) (12.4% vs 45.9%, P=0.026) , and increased cumulative incidence of relapse (P=0.033) . Among the 25 patients with p16 deletion, 14 underwent allo-HSCT and the median survival was 21 months, better than that of patients received chemotherapy alone (12 months) (P=0.030) . Conclusion: This study indicated that deletion of p16 was associated with poor prognosis in adult Ph(+) ALL, and the utility of second-generation TKI (Dasatinib) does not necessarily have an edge on efficacy over Imatinib, but allo-HSCT has the potential of elongating life expectancy. It is an important significance to define the status of p16 in Ph(+) ALL for predicting prognosis and guiding therapy decision-making.目的：探讨p16基因缺失在成人Ph染色体阳性急性淋巴细胞白血病（Ph(+) ALL）中的临床意义。方法：回顾性分析80例Ph(+)ALL伴p16基因缺失患者的临床特征、免疫表型、细胞遗传学、分子生物学改变及其预后。结果： 31.3% Ph(+)ALL患者合并p16基因缺失；p16基因缺失组与非缺失组相比，初诊时高白细胞计数（WBC≥30×10(9)/L）更常见，高表达CD20，更易出现附加染色体异常，其中以累及7、8、19号染色体以及der（22）较为常见；两组诱导缓解率比较差异无统计学意义（P=0.033），p16基因缺失组患者治疗3个疗程后获BCR-ABL融合基因主要分子学反应（MMR）率和完全分子学反应（CMR）率均明显低于非缺失组（P值分别为0.034和0.036），且复发率明显高于非缺失组（P=0.033）；p16基因缺失组使用伊马替尼联合化疗者和使用达沙替尼联合化疗者的MMR、CMR率及复发率差异均无统计学意义（P值均>0.05）；p16基因缺失组患者3年总体生存（OS）率及无病生存（DFS）率分别为37.1%和12.4%，显著低于非缺失组的54.1%和45.9%（P值分别为0.037和0.026）；25例p16基因缺失患者中14例行异基因造血干细胞移植（allo-HSCT），其中位OS时间为21个月，明显长于非移植组患者的12个月（P=0.030）。结论：成人Ph(+)ALL伴p16基因缺失患者预后相对较差，二代酪氨酸激酶抑制剂不能明显改善其疗效，但allo-HSCT能够改善部分患者的生存，明确p16基因缺失状态对于评估预后和指导临床治疗有重要意义。." @default.
• W2612851504 created "2017-05-19" @default.
• W2612851504 creator A5000658599 @default.
• W2612851504 creator A5004396301 @default.
• W2612851504 creator A5010434682 @default.
• W2612851504 creator A5014594183 @default.
• W2612851504 creator A5042449700 @default.
• W2612851504 creator A5055145707 @default.
• W2612851504 creator A5061186599 @default.
• W2612851504 creator A5061881278 @default.
• W2612851504 creator A5067702601 @default.
• W2612851504 creator A5071764592 @default.
• W2612851504 creator A5077487255 @default.
• W2612851504 creator A5078393922 @default.
• W2612851504 creator A5087978892 @default.
• W2612851504 date "2017-03-14" @default.
• W2612851504 modified "2023-10-12" @default.
• W2612851504 title "[Clinical analysis of adult Philadelphia chromosome-positive acute lymphoblastic leukemia with p16 gene deletion]." @default.
• W2612851504 cites W1673031009 @default.
• W2612851504 cites W1686733339 @default.
• W2612851504 cites W1784814409 @default.
• W2612851504 cites W1947148609 @default.
• W2612851504 cites W1973850616 @default.
• W2612851504 cites W199452398 @default.
• W2612851504 cites W2003041273 @default.
• W2612851504 cites W2005395372 @default.
• W2612851504 cites W2017838975 @default.
• W2612851504 cites W2019517928 @default.
• W2612851504 cites W2038403427 @default.
• W2612851504 cites W2050136144 @default.
• W2612851504 cites W2051262530 @default.
• W2612851504 cites W2060383229 @default.
• W2612851504 cites W2065851457 @default.
• W2612851504 cites W2066848701 @default.
• W2612851504 cites W2068851836 @default.
• W2612851504 cites W2107227659 @default.
• W2612851504 cites W2117824893 @default.
• W2612851504 cites W2117908847 @default.
• W2612851504 cites W2140423522 @default.
• W2612851504 cites W2147270774 @default.
• W2612851504 cites W2148743957 @default.
• W2612851504 cites W2162567359 @default.
• W2612851504 cites W2419226061 @default.
• W2612851504 doi "https://doi.org/10.3760/cma.j.issn.0253-2727.2017.03.006" @default.
• W2612851504 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7348375" @default.
• W2612851504 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28395443" @default.
• W2612851504 hasPublicationYear "2017" @default.
• W2612851504 type Work @default.
• W2612851504 sameAs 2612851504 @default.
• W2612851504 citedByCount "0" @default.
• W2612851504 crossrefType "journal-article" @default.
• W2612851504 hasAuthorship W2612851504A5000658599 @default.
• W2612851504 hasAuthorship W2612851504A5004396301 @default.
• W2612851504 hasAuthorship W2612851504A5010434682 @default.
• W2612851504 hasAuthorship W2612851504A5014594183 @default.
• W2612851504 hasAuthorship W2612851504A5042449700 @default.
• W2612851504 hasAuthorship W2612851504A5055145707 @default.
• W2612851504 hasAuthorship W2612851504A5061186599 @default.
• W2612851504 hasAuthorship W2612851504A5061881278 @default.
• W2612851504 hasAuthorship W2612851504A5067702601 @default.
• W2612851504 hasAuthorship W2612851504A5071764592 @default.
• W2612851504 hasAuthorship W2612851504A5077487255 @default.
• W2612851504 hasAuthorship W2612851504A5078393922 @default.
• W2612851504 hasAuthorship W2612851504A5087978892 @default.
• W2612851504 hasConcept C104317684 @default.
• W2612851504 hasConcept C120665830 @default.
• W2612851504 hasConcept C121332964 @default.
• W2612851504 hasConcept C126322002 @default.
• W2612851504 hasConcept C138626823 @default.
• W2612851504 hasConcept C143998085 @default.
• W2612851504 hasConcept C150194340 @default.
• W2612851504 hasConcept C2776694085 @default.
• W2612851504 hasConcept C2777583451 @default.
• W2612851504 hasConcept C2778461978 @default.
• W2612851504 hasConcept C2778729363 @default.
• W2612851504 hasConcept C2778904597 @default.
• W2612851504 hasConcept C2779536868 @default.
• W2612851504 hasConcept C2781107101 @default.
• W2612851504 hasConcept C2909962599 @default.
• W2612851504 hasConcept C30481170 @default.
• W2612851504 hasConcept C54355233 @default.
• W2612851504 hasConcept C55548728 @default.
• W2612851504 hasConcept C61511704 @default.
• W2612851504 hasConcept C71924100 @default.
• W2612851504 hasConcept C72563966 @default.
• W2612851504 hasConcept C86803240 @default.
• W2612851504 hasConcept C88879693 @default.
• W2612851504 hasConcept C90924648 @default.
• W2612851504 hasConceptScore W2612851504C104317684 @default.
• W2612851504 hasConceptScore W2612851504C120665830 @default.
• W2612851504 hasConceptScore W2612851504C121332964 @default.
• W2612851504 hasConceptScore W2612851504C126322002 @default.
• W2612851504 hasConceptScore W2612851504C138626823 @default.
• W2612851504 hasConceptScore W2612851504C143998085 @default.
• W2612851504 hasConceptScore W2612851504C150194340 @default.
• W2612851504 hasConceptScore W2612851504C2776694085 @default.
• W2612851504 hasConceptScore W2612851504C2777583451 @default.
• W2612851504 hasConceptScore W2612851504C2778461978 @default.

• next